HEAD-TO-HEAD COMPARATIVE EFFICACY OF GOLIMUMAB VS. TOFACITINIB IN REACTIVE ARTHRITIS: A 52-WEEK REAL-WORLD COHORT STUDY FROM UZBEKISTAN

dc.contributor.author	Khalmurad Akhmedov, Javohir Mullokulov, Maruf Anorboev
dc.date.accessioned	2025-12-14T18:30:15Z
dc.date.available	2025-12-14T18:30:15Z
dc.date.issued	2025
dc.identifier.citation	Toshkent	en_US
dc.identifier.issn	2181-1326
dc.identifier.uri	http://repo.tma.uz/xmlui/handle/1/2633
dc.description.abstract	Reactive arthritis (ReA) is an inflammatory joint disease triggered by urogenital or enteric infections. This 52-week prospective cohort from Uzbekistan compared the TNF-a inhibitor golimumab and the JAK inhibitor tofacitinib in 60 ReA patients. Both treatments produced significant reductions in DAREA, BASDAI, and inflammatory markers. Mean DAREA decreased from 4.7 to 1.6 with golimumab and from 4.5 to 1.1 with tofacitinib (p < 0.001). Cytokine levels (TNF-a, IL-17A) declined by over 40%, correlating with clinical improvement. Adverse events were mild, and no thromboembolic or fatal outcomes occurred. Tofacitinib achieved slightly faster and deeper responses, supporting its role as an effective oral alternative to biologic therapy in resource-limited settings	en_US
dc.language.iso	en	en_US
dc.subject	: Reactive arthritis; Golimumab; Tofacitinib; TNF-a inhibitor; JAK inhibitor; Cytokines; Real-world study; Uzbekistan.	en_US
dc.title	HEAD-TO-HEAD COMPARATIVE EFFICACY OF GOLIMUMAB VS. TOFACITINIB IN REACTIVE ARTHRITIS: A 52-WEEK REAL-WORLD COHORT STUDY FROM UZBEKISTAN	en_US
dc.type	Article	en_US